News about Global Pharma

USFDA Approves Bristol Myers Squibb's 'Opdivo Qvantig Injection'

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use, a combination product of nivolumab co-formulated with recombinant human hyaluronidase (rHuPH20).

Global Pharma | 30/12/2024 | By Manvi |  207

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849

IDEAYA Biosciences has secured an exclusive global license (outside China) from Jiangsu Hengrui Pharmaceuticals for SHR-4849, a novel DLL3-targeting ADC program with promising early clinical results in solid tumours, including small cell lung cancer.

Global Pharma | 30/12/2024 | By Manvi |  200

Hoth Therapeutics Partners with the Department of Veterans Affairs to Develop Obesity Treatment

Hoth Therapeutics, Inc., a biopharmaceutical company, has secured an exclusive patent license agreement with the US Department of Veterans Affairs and Emory University for groundbreaking technology targeting obesity and related health conditions.

Global Pharma | 27/12/2024 | By Manvi |  112

AusperBio Bags USD 73 Million in Series B Financing for Chronic Hepatitis B

This financing followed the company's Series A round completed in July this year, demonstrating continued investor confidence in its proprietary platform and strategic direction.

Global Pharma | 27/12/2024 | By Aishwarya |  245

Meiji Seika Pharma Establishes Local Subsidiary Taiwan Meiji Pharma

Meiji Seika Pharma aims to become ‘a company in Asia in the field of infectious diseases’ as part of the ‘Meiji Group 2026 Vision’ targeting the year 2026.

Global Pharma | 26/12/2024 | By Aishwarya |  620

Bio-Thera Solutions, Tabuk Pharmaceutical Partner to Commercialise BAT2206 in Saudi Arabia

Bio-Thera Solutions Inc. has partnered with Tabuk Pharmaceutical Manufacturing Company, a fully-owned subsidiary of Astra Industrial Group, for BAT2206, its ustekinumab biosimilar.

Global Pharma | 26/12/2024 | By Abha |  958

Ractigen Therapeutics Doses First Patient in Phase I Clinical Trial for RAG-17 in SOD1-ALS

RAG-17 received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) in March 2023, followed by the FDA's clearance of its Investigational New Drug (IND) application.

Global Pharma | 26/12/2024 | By Aishwarya |  628

Porton Pharma Solutions and Dragon Sail Pharmaceutical Partner to Advance ADC Drug Ecosystem

This collaboration aims to carry out in-depth cooperation in the research, development, production, and supply chain integration of antibody-drug conjugates (ADC).

Global Pharma | 24/12/2024 | By Manvi |  582

TekniPlex Healthcare Emphasizes Two EU-Based Capacity and Capabilities Expansions at Pharmapack Europe

At Stand E97 , the company will highlight its efforts to meet growing demand for sophisticated vials, bellow bottles and cleanroom-produced multilayer blown films, and also showcase products from its existing portfolio of healthcare packaging solutions.

Global Pharma | 24/12/2024 | By Manvi |  411

Ellipses Introduces Pioneering Clinical Trial Programme in Middle East

The trial will focus on Ellipses' next generation selective RET inhibitor (SRI), EP0031/A400, a potential treatment of RET-altered tumours, most prevalent in non-small cell lung cancer and thyroid cancer.

Global Pharma | 24/12/2024 | By Aishwarya |  266